Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Small

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    2,675 result(s) found for: Small. Displaying page 1 of 134.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2007-005245-37 Sponsor Protocol Number: M06-880 Start Date*: 2008-04-17
    Sponsor Name:Abbott GmbH & Co. KG
    Full Title: An Open-Label, Randomized, Phase 2 Study of Efficacy and Tolerability of ABT-869 in Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
    Medical condition: Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061873 Non-small cell lung cancer LLT
    9.1 10059515 Non-small cell lung cancer metastatic LLT
    9.1 10029514 Non-small cell lung cancer NOS LLT
    9.1 10029515 Non-small cell lung cancer recurrent LLT
    9.1 10029516 Non-small cell lung cancer stage 0 LLT
    9.1 10029517 Non-small cell lung cancer stage I LLT
    9.1 10029518 Non-small cell lung cancer stage II LLT
    9.1 10029519 Non-small cell lung cancer stage III LLT
    9.1 10029520 Non-small cell lung cancer stage IIIA LLT
    9.1 10029521 Non-small cell lung cancer stage IIIB LLT
    9.1 10029522 Non-small cell lung cancer stage IV LLT
    9.1 10059515 Non-small cell lung cancer metastatic LLT
    9.1 10029515 Non-small cell lung cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) SE (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-003645-11 Sponsor Protocol Number: 849-012 Start Date*: 2021-07-06
    Sponsor Name:Mirati Therapeutics, Inc.
    Full Title: A Randomized Phase 3 Study of MRTX849 Versus Docetaxel in Patients With Previously Treated Non-Small Cell Lung Cancer With KRAS G12C Mutation
    Medical condition: Advanced Non-Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Trial now transitioned) FR (Trial now transitioned) BE (Trial now transitioned) CZ (Trial now transitioned) PT (Trial now transitioned) PL (Trial now transitioned) IE (Trial now transitioned) GR (Trial now transitioned) NL (Trial now transitioned) IT (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2004-001331-36 Sponsor Protocol Number: EORTC 08021 - ILCP Start Date*: 2005-02-17
    Sponsor Name:IST. DI RICERCHE FARMACOLOG. M. NEGRI
    Full Title: A randomized phase III study of follow-up with or without Gefitinib (IressaTM) following chemotherapy in patients with advanced non-small cell lung cancer.
    Medical condition: Non small cell lung cancer, advanced.
    Disease: Version SOC Term Classification Code Term Level
    6.1 10061873 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-001259-34 Sponsor Protocol Number: FoRT01/2016 Start Date*: 2016-08-31
    Sponsor Name:FONDAZIONE RICERCA TRASLAZIONALE (FORT)
    Full Title: PF-06463922 for crizotinib pretreated ROS1 positive non-small-cell lung cancer: a phase II Trial (PFROST)
    Medical condition: ROS1 positive non-small-cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-004157-16 Sponsor Protocol Number: CABinMET Start Date*: 2018-02-21
    Sponsor Name:FONDAZIONE RICERCA TRASLAZIONALE (FORT)
    Full Title: Phase II single arm study with CABozantinib in Non-Small Cell Lung Cancer patients with MET deregulation
    Medical condition: Stage III B or stage IV non-small cell lung cancer (not a candidate for local therapies with curative intent)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-003495-35 Sponsor Protocol Number: IEO S311/306 Start Date*: 2007-06-05
    Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA
    Full Title: PHASE II TRIAL OF BORTEZOMIB (VELCADE) IN COMBINATION WITH CHLORAMBUCIL IN PATIENTS WITH RELAPSED/REFRACTORY WALDENSTROMﾑS MACROGLOBULINEMIA OR SMALL LYMPHOCYTIC LYMPHOMA. A MULTICENTER STUDY.
    Medical condition: WALDENSTROMﾑS MACROGLOBULINEMIA OR SMALL LYMPHOCYTIC LYMPHOMA
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003908 B-cell small lymphocytic lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-011895-31 Sponsor Protocol Number: CLIN903 LCM201 Start Date*: 2009-07-08
    Sponsor Name:STEBA BIOTECH
    Full Title: EVALUATION OF THE SAFETY AND EFFICACY OF WST11 MEDIATED VASCULAR TARGETED PHOTODYNAMIC THERAPY ON OBSTRUCTING ENDOBRONCHIAL NON-SMALL CELL LUNG CANCER
    Medical condition: Obstructive endobronchial non-small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029514 Non-small cell lung cancer NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-003795-49 Sponsor Protocol Number: IFCT-1603 Start Date*: 2016-12-16
    Sponsor Name:IFCT
    Full Title: A randomized multicenter, open label, controlled and non-comparative phase II study of anti–PDL1 ATEZOLIZUMAB (MPDL3280A) or chemotherapy as second-line therapy in patients with small cell lung can...
    Medical condition: Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041067 Small cell lung cancer PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041068 Small cell lung cancer extensive stage PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041069 Small cell lung cancer limited stage PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2014-001263-12 Sponsor Protocol Number: FoRT01/2014 Start Date*: 2014-08-07
    Sponsor Name:Fondazione Ricerca Traslazionale (FoRT)
    Full Title: Crizotinib in pretreated metastatic non-small-cell lung cancer with MET amplification or ROS1 translocation (METROS)
    Medical condition: Pretreated metastatic non-small-cell lung cancer with MET amplification or ROS1 translocation
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-004722-27 Sponsor Protocol Number: ICT-BEM-2004-01 Start Date*: 2005-05-12
    Sponsor Name:Instituto Científico y Tecnológico de Navarra, S.A.
    Full Title: Randomised, open, multicenter, sequential trial assessing the safety and efficacy of bemiparin on the response to the treatment in patients diagnosed with localized small cell carcinoma of the lung.
    Medical condition: Small cell carcionoma of the lung medDRA CLASSIFICATION CODE: PT 10041071
    Disease: Version SOC Term Classification Code Term Level
    4.0 10041071 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-005942-22 Sponsor Protocol Number: MK8669-021 Start Date*: 2009-01-15
    Sponsor Name:MERCK & CO., INC.
    Full Title: A Randomized Discontinuation Phase II Trial of Deforolimus in Non-Small Cell Lung Cancer (NSCLC) Patients with KRAS Mutations.
    Medical condition: Non-Small Cell Lung Cancer (NSCLC) Patients with KRAS Mutations
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029514 Non-small cell lung cancer NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) ES (Prematurely Ended) DE (Prematurely Ended) DK (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2007-007139-26 Sponsor Protocol Number: S075LBH501 Start Date*: 2008-04-17
    Sponsor Name:SENDO TECH
    Full Title: A phase II study of the histone deacetylase inhibitor Panobinostat (LBH589) in patients with advanced Small Cell Lung Cancer (SCLC)
    Medical condition: SCLC patients
    Disease: Version SOC Term Classification Code Term Level
    9.1 10041070 Small cell lung cancer recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) DE (Completed) GR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-005614-29 Sponsor Protocol Number: CC-486-NSCL-001 Start Date*: 2015-11-19
    Sponsor Name:Celgene Corporation
    Full Title: A Phase 2 multicenter, randomized, placebo controlled, double-blind study to assess the safety and efficacy of CC-486 (oral azacitidine) in combination with pembrolizumab (MK-3475) versus pembroliz...
    Medical condition: Second-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC).
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066490 Progression of non-small cell lung cancer LLT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029521 Non-small cell lung cancer stage IIIB PT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029515 Non-small cell lung cancer recurrent PT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Ongoing) ES (Completed) GR (Completed) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-002708-33 Sponsor Protocol Number: POP 01 Start Date*: 2007-07-19
    Sponsor Name:ISTITUTI FISIOTERAPICI OSPITALIERI
    Full Title: RANDOMIZED PHASE III TRIAL OF PREOPERATIVE VERSUS POSTOPERATIVE CHEMOTHERAPY WITH CISPLATIN AND GEMCITABINE IN STAGE IB-IIIA NON-SMALL CELL LUNG CANCER NSCLC
    Medical condition: Neoadjuvant treatmento for early stage non small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061873 Non-small cell lung cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-002552-24 Sponsor Protocol Number: PKAPIR Start Date*: 2016-12-16
    Sponsor Name:Centre Georges François Leclerc
    Full Title: Pemetrexed (Alimta®) in maintenance in patients with impaired renal function: multicenter randomized Phase 4 study comparing two strategies for dose calculation
    Medical condition: Patients with non-small lung cell cancer
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-004847-47 Sponsor Protocol Number: DOCET_L_01704 Start Date*: 2007-06-12
    Sponsor Name:Jeroen Bosch - Groot Ziekengasthuis
    Full Title: A phase II study of docetaxel/carboplatin as secondline treatment in patients with refractory or relapsed SCLC
    Medical condition: patients with refractory or relapsed small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    8.1 10041067 Small cell lung cancer LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-001105-96 Sponsor Protocol Number: EMR62202-046 Start Date*: 2004-09-14
    Sponsor Name:Merck KGaA
    Full Title: Open, randomized, controlled, multicenter phase III study comparing cisplatin / vinoelbine plus cetuximab versus cisplatin / vinorelbine as first-line treament for patients with EGFR-expessing adva...
    Medical condition: Epidermal growth factor receptor-expressing advanced non-small cell lung cancer.
    Disease: Version SOC Term Classification Code Term Level
    7.0 10061873
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) SK (Completed) SE (Completed) AT (Completed) IT (Completed) ES (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-005941-39 Sponsor Protocol Number: 646-007-00 Start Date*: 2008-06-30
    Sponsor Name:Merck & Co., Inc.
    Full Title: An Open Label, Randomized Phase I/IIa Trial Evaluating MK-0646 in Combination With Erlotinib (TARCEVA™) for Patients With Recurrent Non-Small Cell Lung Cancer"
    Medical condition: Non-small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061873 Non-small cell lung cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) SE (Completed) DK (Completed) FR (Completed) NL (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-008920-34 Sponsor Protocol Number: 09.01 Start Date*: 2009-03-19
    Sponsor Name:Odense University Hospital
    Full Title: Induction chemotherapy with Carboplatin and Navelbine Oral® followed by concomitant Navelbine Oral® and irradiation in local-regionally advanced non-small cell lung cancer. A randomized phase II s...
    Medical condition: Local-regionally advanced non-small cell lung cancer.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061873 Non-small cell lung cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2006-004963-68 Sponsor Protocol Number: 26866138-LUC-2006 Start Date*: 2007-10-16
    Sponsor Name:Prof Vassilis Georgoulias
    Full Title: A Phase II, Open-Label Trial of Bortezomib (Velcade®) in Combination with Gemcitabine and Cisplatin in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer.
    Medical condition: First Line treatment for Locally Advanced or Metastatic Non-Small Cell Lung Cancer.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10061873 Non-small cell lung cancer LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 03 01:41:54 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA